Extend Biosciences Announces Positive Data from Phase 1 Trial of EXT608 for the Treatment of Hypoparathyroidism
Extend Biosciences announces positive interim clinical data from the Phase 1 trial of EXT608 for the rare disease hypoparathyroidism.
Extend Biosciences announces positive interim clinical data from the Phase 1 trial of EXT608 for the rare disease hypoparathyroidism.